VG@nAu-based fluorescent biosensor for grading Alzheimer's disease by detecting P-tau181 protein in clinical samples
Analytica Chimica Acta · 2025
DOI: 10.1016/j.aca.2025.343654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytica Chimica Acta, 2025. Verfasst von Yibiao Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Longgang Clinical Institute of Shantou University Medical College, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, 518116, China. Hauptthemen laut MEDLINE: Biosensing Techniques, Alzheimer Disease, tau Proteins, Gold. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Shenzhen Science and Technology Innovation Committee.
Themen: Demenz
Abstract (Originalsprache)
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder with a very long duration, posing a serious threat to people's life and health. To date, no medicine that can cure or reverse the disease has been developed or reported, so early diagnosis and timely intervention are essential. The concentration of Phosphorylated tau181 (P-tau181) in blood has been approved by FDA as a standard for assisting clinical diagnosis of AD. RESULTS: In this study, a fluorescence biosensor based on vertical graphene-modified nano-gold film (VG@nAu) was developed for the grading of AD diagnosis by detecting P-tau181 protein in the blood. The VG@nAu substrate that produces hundreds of times IR800 molecular compared with a glass substrate, which is prepared by sputtering nano-gold onto vertical graphene surface. The detection limit of this fluorescence biosensor for P-tau181 is 0.82 pg/mL. The sensor also shows excellent selectivity and stability. Moreover, we analyzed the levels of P-tau181 in 16 clinical samples divided into four groups (HC group, SCD group, MCI group, and AD group) and found significant differences in P-tau181 levels. The grouping result based on the detection results using this biosensor is consistent with the grouping results of the clinical doctors. SIGNIFICANCE: This study achieves ultrasensitive detection of P-tau181 protein by constructing a fluorescent biosensor, which validates the feasibility of the VG@nAu-based fluorescence biosensor for the grading of AD diagnosis. This research provides a promising tool for ultrasensitive detecting biomarkers in clinical samples, indicating significant potential for its use in related diagnosing disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Longgang Clinical Institute of Shantou University Medical College, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, 518116, China.
- Institute for Advanced Study (IAS), College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, 518060, China.
- Institute for Advanced Study (IAS), College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, 518060, China. Electronic address: liuqiong@szu.edu.cn.
- Institute for Advanced Study (IAS), College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, 518060, China. Electronic address: xutailin@szu.edu.cn.
Förderung
- Shenzhen Science and Technology Innovation Committee
Zitieren
APA
Liu, Y., Liu, X., Liu, Q., & Xu, T. (2025). VG@nAu-based fluorescent biosensor for grading Alzheimer's disease by detecting P-tau181 protein in clinical samples. Analytica Chimica Acta. https://doi.org/10.1016/j.aca.2025.343654
Vancouver
Liu Y, Liu X, Liu Q, Xu T. VG@nAu-based fluorescent biosensor for grading Alzheimer's disease by detecting P-tau181 protein in clinical samples. Analytica Chimica Acta. 2025. doi:10.1016/j.aca.2025.343654
BibTeX
@article{Liu2025,
author = {Liu, Yibiao and Liu, Xingyun and Liu, Qiong and Xu, Tailin},
title = {VG@nAu-based fluorescent biosensor for grading Alzheimer's disease by detecting P-tau181 protein in clinical samples},
journal = {Analytica Chimica Acta},
year = {2025},
doi = {10.1016/j.aca.2025.343654}
}
EUVIMED